Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.78 |
| ▸ | ITK | Q08881 | 7/20 | 0.67 |
| ▸ | BTK | Q06187 | 5/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | BLK | P51451 | 2/20 | 0.60 |
| ▸ | BMX | P51813 | 2/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.55 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 0.55 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.55 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228637 | 1.00 | EGFR (0.78) | EGFRITKBTKJAK2BLK | |
| SCHEMBL21443514 | 0.89 | EGFR (0.60) | EGFRITKBTKJAK2BLK | |
| SCHEMBL16391084 | 0.88 | EGFR (0.69) | EGFRITKBTKJAK2BLK | |
| SCHEMBL29722245 | 0.87 | EGFR (1.00) | EGFRITKBTKJAK3FGFR2 | |
| SCHEMBL13165553 | 0.87 | EGFR (1.00) | EGFRITKBTKJAK3FGFR2 | |
| SCHEMBL18165638 | 0.87 | EGFR (0.65) | EGFRITKBTKJAK2BLK | |
| SCHEMBL16391080 | 0.85 | EGFR (0.65) | EGFRITKBTKJAK2BLK | |
| SCHEMBL12519726 | 0.83 | EGFR (0.84) | EGFRITKBTKJAK3 | |
| SCHEMBL12519479 | 0.81 | EGFR (0.70) | EGFRITKBTKJAK2BLK | |
| SCHEMBL2230134 | 0.81 | EGFR (1.00) | EGFRITKBTKJAK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EGFR 460/4885ITK 317/4885BTK 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.